Skip to main content

CX.5 SHAPE trial reaches a randomization milestone

500 Patients randomized on the SHAPE study!

Congratulations to Dr. Dounia Skalli and the team at centre hospitalier intercommunal de Créteil, France for enrolling the 500th patient to the SHAPE study! On behalf of the SHAPE trial committee, we would like to thank you for your tremendous and unwavering support of our trial.

About the trial

A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early Stage Cervical Cancer. (SHAPE)

The reason this study is being done is to see if a simple hysterectomy is as good as a radical hysterectomy in preventing cancer of the cervix from returning, and whether, because less tissue surrounding the uterus is removed during surgery, there are fewer side-effects after the surgery and in the long-term.

Eligibility: Histologically confirmed adenocarcinoma, squamous, or adenosquamous cancer of the cervix. Diagnosis has been made by LEEP, cone or cervical biopsy and has been reviewed and confirmed by the local reference gynecological pathologist.

https://www.ctg.queensu.ca/public/gynecologic/gynecologic-disease-site